A b s t r a c t
Essentially all cases of precursor B-lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL) demonstrate multiple immunophenotypic aberrancies relative to their normal counterpart, maturing B-cell precursors (hematogones). [1] [2] [3] Hematogone populations demonstrate a characteristic and highly reproducible maturation pattern, whereas neoplastic lymphoblasts exhibit maturation arrest (eg, uniform expression of terminal deoxynucleotidyl transferase [TdT] and/or CD34), immunophenotypic asynchrony (coexpression of early and late antigens that are mutually exclusive in hematogones), [2] [3] [4] [5] [6] overexpression or underexpression of normally expressed antigens, and frequent expression of cross-lineage antigens. Thus, neoplastic lymphoblasts can be consistently distinguished from hematogones by multicolor flow cytometry (FC) using appropriately selected antibody panels.
The use of FC to monitor minimal residual disease (MRD) in patients with B-ALL assumes that leukemic cells retain immunophenotypic aberrancy during and after therapy. The stability of these leukemia-associated immunophenotypes is, thus, of major interest for purposes of targeted follow-up analyses. This has been addressed in several studies. [7] [8] [9] [10] [11] [12] [13] [14] [15] The reported immunophenotypic changes include loss of CD10, HLA-DR, TdT, and CD20 and gain or loss of myeloid antigens. However, none of these studies has comprehensively assessed the patterns of immunophenotypic aberrancy of B-ALL relative to the normal immunophenotype of hematogones. We believe a systematic comparison of the immunophenotypes of lymphoblasts and hematogones permits detection of a wide spectrum of immunophenotypic aberrancies at diagnosis, which would be expected to enhance the ability to detect MRD. Detailed knowledge of the stability of leukemia-associated immunophenotypes between diagnosis
Materials and Methods
The files of the Clinical Flow Cytometry Laboratory at the University of Texas Southwestern Medical Center, Dallas, were searched for all relapsed B-ALL cases in which both diagnostic and relapsed specimens were analyzed by multicolor FC between April 1994 and February 2004. Only overt morphologic relapses were included in the study (ie, low-level disease detected immunophenotypically without morphologic evidence of residual disease was not considered relapse for the purposes of case selection). This yielded 51 cases.
Flow Cytometry
Peripheral blood (PB) or bone marrow (BM) specimens were processed using previously described methods. 2 The amount of antibody added was determined by the manufacturer's recommendations, with titration used when needed. At least 30,000 events were routinely acquired using a FACSCalibur (4-color) or FACSort (3-color) flow cytometer (Becton Dickinson [BD] Immunocytometry Systems, San Jose, CA) with CellQuest software (BD). Most cases were analyzed using 4-color flow cytometry.
Antibodies to the following antigens conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein, and allophycocyanin were used, all obtained from BD unless otherwise specified: CD10 (W8E7), CD19 (SJ25C1), CD20 (L27), CD22 (S-HCL-1), CD79a (SNB), polyclonal κ and λ light chains (Beckman-Coulter, Miami, FL), TdT (Supertech, Bethesda, MD), CD34 (8G12), CD38 (HB7), CD45 (2D1), HLA-DR (L243), CD11b (D12), CD13 (L138), CD14 (MφP9), CD15 (MMA), CD36 (FA6.152, BeckmanCoulter), CD56 (MY31), CD61 (RUUPL7F12), CD64 (10.1, Ancell, Bayport, MN, or Caltag, Burlingame, CA), myeloperoxidase (MPO; MPO7, DAKO, Glastrup, Denmark), CD1a (H1149), CD2 (S5-2), CD3 (SK7), CD4 (SK3), CD5 (L17F12), CD7 (4H9), and CD8 (SK1). A portion of every specimen was stained with isotype-matched fluorescent control monoclonal antibodies. At diagnosis, 47 cases were stained with complete panels and 4 with limited panels. At relapse, 49 cases were analyzed with complete surface marker panels; generally, intracellular antigens (CD3, CD22, CD79a, MPO, and TdT) were not assessed at relapse. At diagnosis and relapse, 45 cases were analyzed with complete surface panels.
Data analysis was performed using Paint-a-Gate software (BD). Distinct cell populations (clusters) were identified based on any combination of forward and orthogonal light scatter properties and fluorescence intensity with various antibody combinations. An antigen was considered positive in a population when at least 10% of the cluster of interest exceeded a 2% isotypic control threshold. Percentages of various cell types were determined based on total events.
Aberrancy at diagnosis and relapse was defined as expression patterns deviating from those seen in normal maturing B-cell precursors (hematogones) ❚Image 1❚. This included antigen asynchrony, underexpression or overexpression or loss of individuals antigens, abnormal patterns of expression of CD34 or TdT, and expression of myeloid or T lymphoid-associated antigens. Overexpression or underexpression was defined as at least a 0.5 log increase or decrease of intensity compared with that of hematogones. Because of the possibility of shifts in relative fluorescence over time owing to instrument or reagent changes, when possible, levels of antigen expression were compared with internal normal cell populations (eg, CD45 on granulocytes). When necessary, the level of antigen expression was compared with that of hematogones in other BM samples analyzed on the same day as the study cases. Abnormal CD34 or TdT patterns were defined as uniform expression of these antigens on the entire blast population (maturation arrest) or an abnormal continuous pattern of expression (vs the biphasic pattern seen in hematogones 3 ). Loss of aberrancy was defined as reversion of an abnormality present at diagnosis to an essentially normal pattern at relapse. Minor changes in aberrant patterns were not considered changes if the overall pattern remained aberrant.
Statistical Analysis
Categorical variables were analyzed with 2-tailed χ 2 tests or Fisher exact tests when applicable. P values less than .05 were considered statistically significant.
Results

Patient Characteristics
The study included 51 cases with both diagnostic and relapsed specimens analyzed by multicolor FC. The patients were 27 males and 24 females, aged 1 to 65 years (median, 14 years). Of the 51 patients, 30 were younger than 18 years at B-ALL diagnosis.
Immunophenotypic Features at Diagnosis
At diagnosis, 41 BM and 10 PB samples were analyzed. Lymphoblasts constituted 15% to 95% of total analyzed events (median, 78%; mean, 70%). A total of 446 aberrancies were present across all cases, with a range of 2 to 14 aberrancies per case (median, 9). The aberrancies found at diagnosis are given in ❚Table 1❚. Most common were abnormalities of TdT, CD34, CD10, CD38, and CD45 and coexpression of myeloid antigens.
Immunophenotypic Features at Relapse
Specimens analyzed at relapse included 43 BM, 6 PB, and 2 cerebrospinal fluid specimens. The interval to relapse ranged from 3 to 73 months (median, 26 months). All cases remained multiply aberrant at relapse, with a range of 2 to 14 aberrancies per case (median, 8) (Table 1 ) ❚Image 2❚, ❚Image 3❚, ❚Image 4❚, and ❚Image 5❚. The frequencies of the various aberrancies at relapse were not significantly different from those at diagnosis. Antibody panels used at relapse allowed assessment of 383 (85.9%) of the initial 446 aberrancies. Of these, 299 (78.1%) were persistent (median, 6 per case; range, 1-11), and 84 (21.9%) were absent (eg, reversion to a normal antigen pattern). The most predominant changes (as a proportion of those initially present) were the loss of 1 or multiple aberrantly expressed myeloid antigens (49%) and the reversion of abnormally expressed HLA-DR, CD19, or CD45 to normal levels (21%, 22%, and 22%, respectively) ❚Table 2❚. Of 45 cases with complete surface panels at both time points, 33 (73%) demonstrated loss of at least 1 aberrancy. In addition, 94 new aberrancies were detected at relapse with a median of 1.5 per case (range, 0-7). Of these, 37 (39%) were detected as a result of different or expanded antibody panels, and, thus, they may have been present at diagnosis. Thus, 57 aberrancies could be documented to be truly new at relapse; these are summarized in ❚Table 3❚. Most common (as a proportion of previously normal cases) were development of abnormal expression of CD10 (43%), CD20 (39%), and CD34 (40%). Of the 45 cases assessed with complete surface panels at diagnosis and relapse, 27 (60%) gained at least 1 new aberrancy at relapse. 
Discussion
In the present study, we analyzed the immunophenotypic changes in B-ALL between diagnosis and relapse using broad antibody panels, with specific reference to the immunophenotypic patterns seen in the normal counterpart of B-ALL, maturing B-cell precursors or hematogones. In our study cohort, B-ALL lymphoblasts at diagnosis demonstrated multiple immunophenotypic aberrancies in all cases (2-14 per case; median, 9) relative to hematogones. The most common aberrancies detected in our study were abnormal expression patterns of CD34 and/or TdT; overexpression or underexpression of CD10, CD22, and HLA-DR; underexpression of CD38 and CD45; asynchronous coexpression of mature and immature antigens (coexpression of CD20 and CD34); and cross-lineage antigen expression. It should be noted that our cases were selected on the basis of development of relapse, and, thus, the specific patterns of aberrancy found in this study should not be construed as necessarily representative of B-ALL in general. However, McKenna et al 16 found aberrancy in all cases in a series of 100 unselected B-ALLs.
Weir et al, 1 despite the use of a limited panel (CD19/ CD45/CD20/CD10 and CD19/CD45/CD9/CD34), found immunophenotypic aberrancy in 99% of B-ALL cases. This supports the notion that aberrancy relative to normal B-cell precursors is an essentially uniform finding in B-ALL. Other studies have found aberrancy rates in the range of 30% to 80%. 7, 8 These lower yields may relate to the definition of aberrancy and/or the use of antibody combinations that did not allow optimal comparison with the immunophenotypic patterns seen in normal hematogones. The large number of aberrancies seen per case in the present study is a result of the relatively broad antibody panels used. The adverse prognostic significance of the presence of MRD has been well established in many studies, and the results of MRD detection by FC have been shown to be generally concordant with molecular techniques using allele-specific oligonucleotides. 15, [17] [18] [19] [20] [21] [22] [23] In these studies, aberrancies (leukemia-associated immunophenotypes) identified at diagnosis were used to monitor MRD in follow-up studies, based on the assumption that leukemia cells retain immunophenotypic aberrancy during and after therapy. However, there is an increasing body of evidence documenting immunophenotypic changes in 30% to 70% of B-ALL cases during progression of the disease. [7] [8] [9] [10] [11] [12] [13] [14] [15] Commonly reported changes include loss of CD10 (16%), HLA-DR (20%), TdT (9%), and CD20 (30%) and gains or losses of myeloid antigens (30%).
In our study, the majority of cases (73%) demonstrated a loss of at least 1 aberrancy, in line with previous studies. However, of the total aberrancies assessed across all cases, nearly 80% were retained at relapse. It should be noted, however, that changes in the pattern or intensity of aberrantly expressed antigens were not tallied as immunophenotypic changes in this study, only reversion of a previously abnormal pattern to normal. Thus, the overall frequency of alterations of immunophenotype is underestimated in this study. Importantly, all cases remained aberrant in multiple respects (median, 8 aberrancies per case; range, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
The implication of our findings and those of other studies is that FC is a useful modality for following up disease status, provided that follow-up studies are not too narrowly targeted. Other authors have reached similar conclusions. Borowitz et al, 13 using a 2-tube panel, focused on shifts in intensity and distribution patterns of antigens in a series of 42 precursor BALLs. They found antigenic shifts in at least 69% of cases but concluded that these would not affect MRD recognition. However, they noted that the application of rigid gating (looking only for a narrowly defined leukemia-associated immunophenotype) would have resulted in missing 36% of MRD cases. In addition, although it is generally assumed that the immunophenotypes seen at relapse reflect what one would encounter in the assessment of MRD, these authors noted that MRD immunophenotypes generally more closely resembled the diagnostic than the relapse patterns. 13 Finally, it is notable that Gaipa et al 24 reported immunophenotypic modulation in B-ALLs at early time points following therapy (eg, day 14). However, these authors also noted that these changes did not interfere with their ability to identify residual leukemic cells.
In addition to losses of specific immunophenotypic aberrancies, we found that 60% of cases showed gains of new aberrancies. Insofar as these serve to enhance the overall degree of immunophenotypic aberrancy of tumor populations, these should not complicate MRD analysis, provided that the frame of reference is normal hematogone maturation and not the original immunophenotype of the blasts.
Potential mechanisms for the instability of antigen expression in acute leukemia after chemotherapy have been proposed in a number of studies. A small fraction of cases have a recurrence of acute leukemia with different cellular and immunophenotypic features (lineage switch). In the majority of these cases, the leukemias are unrelated to the original leukemic clone and represent secondary treatment-related malignancy. 25, 26 However, in some cases, the recurrent leukemia has genetic features identical to those of the original clone. 26, 27 The second possible mechanism is that different leukemic subclones have different chemotherapy sensitivity, and, thus, at relapse, the immunophenotype is representative of the chemotherapy-resistant subclones. The third potential mechanism is inherent genetic instability leading to clonal evolution and associated immunophenotypic modulation.
All B-ALL cases in our study showed multiple immunophenotypic aberrancies at diagnosis. Although 22% of the aberrancies were not present at relapse, new ones were often gained. Overall, changes in aberrancy patterns were detected in 96% of cases. Despite these changes, all cases remained multiply aberrant at relapse. Our studies suggest that although immunophenotypic changes are common in B-ALL, these would not affect MRD detection, provided that followup studies are not too narrowly targeted.
